PCRX

Pacira Biosciences Stock Analysis

AI Rating

Low
  • Quality7/10
  • Growth↓ 0/10
  • Value↓ 4/10
Pacira Biosciences sales and earnings growth
PCRX Growth
Low
  • Revenue Y/Y↓ 3.63%
  • EPS Y/Y↑ 107.44%
  • FCF Y/Y↓ -23.55%
Pacira Biosciences gross and profit margin trends
PCRX Profitability
Neutral
  • Gross margin ↑ 79.40%
  • EPS margin↓ 1.00%
  • ROIC 5Y↓ 1.69%
Pacira Biosciences net debt vs free cash flow
PCRX Risk
Great
  • Debt / Equity↓ 0.6
  • Debt / FCF↓ 1.9
  • Interest coverage↓ 2.0

Pacira Biosciences stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗